Bora Pharmaceuticals Completes $210 Million Purchase of Upsher-Smith

News
Article

Acquisition is expected to strengthen company’s CDMO business, while establishing a footprint in the generics space.

Image Credit: Adobe Stock Images/Vichie81.com

Image Credit: Adobe Stock Images/Vichie81.com

Bora Pharmaceuticals, a contract development and manufacturing organization (CDMO), has officially acquired Upsher-Smith Laboratories, a specialty-brand and generics company, for $210 million.1

Upsher-Smith currently has created 48 generic products with a couple of manufacturing facilities in the state of Minnesota—including one in Maple Grove that it opened last year.2 These plants have the capability to successfully commercialize various dosage forms such as powders (topical and oral) oral solid, and liquid, along with packaging services. With this new deal, Bora can now assist the entire US value chain, including its CDMO business.

This acquisition also provides great exposure for Bora’s commercial Rx business, TWi, with an opportunity for a boost in both marketing capabilities and product development, if there is interesting in growing its product catalogue; in the process, Bora also gains Upsher-Smith’s manufacturing warehouses and a revenue stream via its generic/brand generic portfolio.

“This is a significant milestone for Bora Group, marking the most critical expansion of Bora’s presence in the US market and significantly enhancing Bora’s position as a global competitor with regard to its CDMO business and commercial Rx business,” says Bobby Sheng, chairman and CEO of Bora Group. “Upsher-Smith’s competitiveness is a perfect match to Bora’s long-term growth—its newly-expanded, USFDA-approved manufacturing facilities, with a total capacity of 3.5 billion doses, will be Bora’s first local facility in the US, establishing a crucial stronghold for our global CDMO business. Upsher-Smith’s platform for specialty generics will strengthen TWi’s advantage in the US commercial sale business with a complementary portfolio and differentiated distribution channels.”

References

1. Bora Pharmaceuticals to Acquire US Pharma Manufacturer Upsher-Smith for $210 Million in Transaction to Fuel Global Expansion. Bora Pharmaceuticals. News release. January 16, 2024. Accessed January 23, 2024. https://bora-corp.com/bora-pharmaceuticals-to-acquire-us-pharma-manufacturer-upsher-smith-for-210-million-in-transaction-to-fuel-global-expansion/

2. Upsher-Smith Opens Minnesota Manufacturing Center. Pharmaceutical Commerce. News release. February 8, 2023. Accessed January 23, 2024. https://www.pharmaceuticalcommerce.com/view/upsher-smith-opens-minnesota-manufacturing-center

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.